Interleukin-6 overexpression induces pulmonary hypertension

Area of Science:

• Cardiovascular Biology
• Immunology
• Pulmonary Medicine

Background:

• Elevated interleukin-6 (IL-6) levels are observed in pulmonary artery hypertension (PAH) patients.
• Inflammatory mediators are implicated in PAH pathogenesis across various animal models.

Purpose of the Study:

• To investigate the role of IL-6 in the development of pulmonary vascular disease.
• To determine if IL-6 overexpression can recapitulate key features of PAH.

Main Methods:

• Lung-specific IL-6-overexpressing transgenic mice were compared to wild-type controls.
• Mice were studied under both normoxic and chronic hypoxic conditions.
• Pulmonary vascular remodeling indices, including right ventricular pressures and hypertrophy, were assessed.

Main Results:

• IL-6 overexpression led to elevated right ventricular systolic pressures and hypertrophy, with exacerbation under hypoxia.
• Increased muscularization of the pulmonary arterial tree and distal arteriolar proliferative arteriopathy, including occlusive neointimal lesions, were observed.
• Hypoxia worsened IL-6-induced vascular changes.

Conclusions:

• IL-6 overexpression in the lungs promotes pulmonary vascular remodeling and PAH-like changes.
• These effects are mediated by proproliferative and antiapoptotic signaling pathways.
• IL-6 is a key driver in the pathogenesis and progression of pulmonary vascular disease.